专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明专利

PL2170403T3 Kompozycje i sposoby hamowania ekspresji genów proapoptotycznych 未知
公开(公告)号：PL2170403T3
公开(公告)日：2014-09-30
申请号：PL08763631
申请日：2008-06-26
申请人： QUARK PHARMACEUTICALS INC
发明人： KALINSKI HAGAR , METT IGOR , FEINSTEIN ELENA , ERLICH SHAI DR
IPC分类号： C12N15/113 , A61K31/713

92. 发明专利

SI2170403T1 Sestavki in postopki za inhibicijo ekspresije pro-apoptotskih genov 未知
公开(公告)号：SI2170403T1
公开(公告)日：2014-07-31
申请号：SI200831222
申请日：2008-06-26
申请人： QUARK PHARMACEUTICALS INC
发明人： KALINSKI HAGAR , METT IGOR , FEINSTEIN ELENA , ERLICH SHAI DR
IPC分类号： C12N15/00 , A61K31/00

93. 发明专利

PT2170403E COMPOSIÇÕES E MÉTODOS PARA INIBIÇÃO DA EXPRESSÃO DE GENES PRÓ-APOPTÓTICOS 未知
公开(公告)号：PT2170403E
公开(公告)日：2014-07-17
申请号：PT08763631
申请日：2008-06-26
申请人： QUARK PHARMACEUTICALS INC
发明人： KALINSKI HAGAR , METT IGOR , FEINSTEIN ELENA , ERLICH SHAI
IPC分类号： C12N15/113 , A61K31/713

94. 发明专利

ES2474176T3 Composiciones y métodos para inhibir la expresión de genes pro-apoptóticos 未知
公开(公告)号：ES2474176T3
公开(公告)日：2014-07-08
申请号：ES08763631
申请日：2008-06-26
申请人： QUARK PHARMACEUTICALS INC
发明人： KALINSKI HAGAR , METT IGOR , FEINSTEIN ELENA , ERLICH SHAI
IPC分类号： C12N15/113 , A61K31/713
摘要： Un compuesto ARNip bicatenario que reduce o inhibe la expresión del gen TP53, para usar en la prevención o reducción de la función retardada del injerto en un receptor de un trasplante de riñón, dicho compuesto ARNip tiene la estructura: 5' (N)x -Z 3' (cadena antisentido) 3' Z'-(N')y 5' (cadena sentido) en donde cada uno de N y N' es un ribonucleótido que puede ser modificado o no modificado en su residuo azúcar; en donde cada uno de (N)x y (N')y es un oligonucleótido en el cual cada N o N' consecutivo se une al siguiente N o N' por un enlace covalente; en donde cada uno de x e y es un entero entre 18 y 40; en donde cada uno de (N)x y (N')y los ribonucleótidos alternan entre ribonucléotidos modificados y ribonucléotidos no modificados, cada ribonucléotido modificado es un ribonucléotido modificado en 2'-O-metilo azúcar; en donde cada uno de Z y Z' puede estar presente o ausente, pero si está presente es 1-5 deoxiribonucleótidos covalentemente unidos al terminal 3' del oligonucleótido en la cual está presente; en donde la secuencia de (N)x comprende la secuencia 5' UGAAGGGUGAAAUAUUCUC 3' (sec. con núm. de ident.:2) y la secuencia de (N')y comprende la secuencia 5' GAGAAUAUUUCACCCUUCA 3' (sec. con núm. de ident.:1); y en donde una dosis terapéuticamente eficaz de dicho compuesto ARNip es para administrar intravenosamente al receptor del trasplante de riñón entre 15 minutos y 4 horas después de la revascularización del riñón trasplantado, y de ese modo previene o reduce la función de retardo del injerto en el receptor.

95. 发明专利

AU2012223365A1 Compositions and methods for treating lung disease and injury 未知
公开(公告)号：AU2012223365A1
公开(公告)日：2013-09-12
申请号：AU2012223365
申请日：2012-03-01
申请人： UNIV WASHINGTON , QUARK PHARMACEUTICALS INC
发明人： GELMAN ANDREW E , FEINSTEIN ELENA , ADAMSKY SVETLANA , METT IGOR , KALINSKI HAGAR , AVKIN-NACHUM SHARON
IPC分类号： C12N15/113
摘要： Disclosed herein are therapeutic methods for treating lung diseases, disorders and injury in a mammal, including treatment of acute respiratory distress syndrome (ARDS), acute lung injury, pulmonary fibrosis (idiopathic), bleomycin induced pulmonary fibrosis, mechanical ventilator induced lung injury, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiolitis obliterans after lung transplantation and lung transplantation-induced acute graft dysfunction, including treatment, prevention or prevention of progression of primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response, bronchiolitis obliterans after lung transplantation and/or primary graft dysfunction (PGD) after organ transplantation, in particular in lung transplantation, comprising down-regulating the TLR2 gene or both the TLR2 gene and TLR4 gene. Provided herein are compositions, methods and kits for treating lung diseases, disorders and injury.

96. 发明专利

CA2842954A1 DOUBLE-STRANDED OLIGONUCLEOTIDE COMPOUNDS FOR TREATING HEARING AND BALANCE DISORDERS 未知
公开(公告)号：CA2842954A1
公开(公告)日：2013-02-07
申请号：CA2842954
申请日：2012-08-03
申请人： QUARK PHARMACEUTICALS INC
发明人： FEINSTEIN ELENA , AVKIN-NACHUM SHARON , METT IGOR , KALINSKI HAGAR
IPC分类号： C12N15/113 , A61K31/7088 , A61K31/713 , A61P27/16 , C07H21/00 , C12N5/10
摘要： The present application relates to double stranded nucleic acid compounds, compositions comprising same and methods of use thereof for the treatment of hearing loss in a subject in need thereof. The compounds are preferably chemically synthesized and modified dsRNA molecules which inhibit expression of a gene expressed selected from the group consisting of HES1, HES5, HEY1, HEY2, ID1, ID2, ID3, CDKN1B, and NOTCHl.

97. 发明专利

AU2009308380A1 Methods for treating eye disorders 未知
公开(公告)号：AU2009308380A1
公开(公告)日：2010-04-29
申请号：AU2009308380
申请日：2009-10-22
申请人： QUARK PHARMACEUTICALS INC
发明人： FEINSTEIN ELENA , ALPERT EVGENIA , METT IGOR , BAR-ILAN AMIR , SPIVAK IGOR , KALINSKI HAGAR , SLAGER NETANJA
IPC分类号： A61K31/711 , C12N15/113
摘要： The present invention relates to compositions and methods for inhibiting loss of a retinal ganglion cell in a subject, comprising non-invasively applying to the surface of the eye of the subject an ophthalmic composition comprising a therapeutically effective amount of at least one siRNA which down regulates expression of a target gene associated with loss of the retinal ganglion cell, thereby inhibiting loss of the retinal ganglion cell in the subject. The methods of the invention also relate to the use of chemically modified siRNA compounds possessing structural motifs which down-regulate the expression of human genes expressed in retinal tissue in the mammalian eye.

98. 发明专利

AU2009227549A1 Novel siRNA compounds for inhibiting RTP801 未知
公开(公告)号：AU2009227549A1
公开(公告)日：2009-09-24
申请号：AU2009227549
申请日：2009-03-17
申请人： QUARK PHARMACEUTICALS INC
发明人： SKALITER RAMI , METT IGOR , KALINSKI HAGAR , FEINSTEIN ELENA
IPC分类号： A61K48/00
摘要： The present invention provides chemically modified siRNA compounds that target RTP801 and pharmaceutical compositions comprising same useful for treating microvascular disorders, eye diseases, hearing impairment, neurodegenerative diseases and disorders, spinal cord injury and respiratory conditions.

99. 发明专利

GB2450840A8 Screening systems utilizing rtp801 未知
公开(公告)号：GB2450840A8
公开(公告)日：2009-01-21
申请号：GB0820038
申请日：2007-05-11
申请人： QUARK PHARMACEUTICALS INC
发明人： WECHSLER RONI , METT IGOR
IPC分类号： G01N33/68 , C12Q1/37 , G01N33/50 , G01N33/574 , G01N33/74
摘要： RTP801 represents a unique gene target for hypoxia-inducible factor-1 (HIF-1). Down-regulation of the mTOR pathway activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of RTP801. The present invention relates to screening systems utilizing RTP801 and/or RTP801 interactors and/or RTP801 biological activity, to drug candidates identified by such screening systems, and to the use of such drug candidates in the treatment of various disorders.

100. 发明专利

CA2666270A1 NOVEL SIRNAS AND METHODS OF USE THEREOF 未知
公开(公告)号：CA2666270A1
公开(公告)日：2008-05-02
申请号：CA2666270
申请日：2007-10-25
申请人： QUARK PHARMACEUTICALS INC
发明人： SKALITER RAMI , METT IGOR , FEINSTEIN ELENA , IDELSON GREGORY HIRSH , KALINSKI HAGAR
IPC分类号： C07H21/02 , C12N15/113 , C12N15/12 , C12N15/63
摘要： The invention relates to compounds, in particular siRNAs, which inhibit t he expression of specific human genes. The invention also relates to pharmac eutical compositions comprising such compounds and a pharmaceutically accept able carrier. The present invention also provides a method of treating and/or preventing the incidence or severity of various diseases or conditions ass ociated with the genes and/or symptoms associated with such diseases or cond itions comprising administering to a subject in need of treatment for such d isease or condition and/or symptom the compound or the pharmaceutical compos ition in a therapeutically effective dose so as to thereby treat the subject . The invention also provides antibodies which inhibit specified human polyp eptides and pharmaceutical compositions comprising one or more such antibodi es.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式